Industry news

Three British biotech leaders will develop a new class of medicines

GMP News

Three leading British biotechnology businesses (CHAIN Biotech, Porton Biopharma and Scitech) have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome.

Local drugmakers dominate in segment of vital drugs in Russia

Remedium

The share of domestic drugs in the list of vital drugs available in the Russian pharmaceutical market in 2017 reached a record high of 84% for the last 20 years, according to recent statements of the Russian Minister of Industry and Trade Denis Manturov and some senior officials of the Ministry of Health, reports The Pharma Letter’s local correspondent.

Russia's president urges to create national program to fight cancer

Remedium

A nationwide program to fight cancer must be implemented in Russia, President Vladimir Putin said in his State of the Nation Address to the Federal Assembly.

New manufacturing facility will be established in Tatarstan

GMP News

During his working visit to Switzerland, the President of the Republic of Tatarstan Rustam Minnikhanov visited the headquarters of Ferring, a pharmaceutical company. In the Republic of Tatarstan, Ferring is represented by Nanopharma Development, a company. The production facility is located in Khimgrad Technopolis. The first industrial lot of a drug for the needs of transplantology was manufactured in Q3 2017.

Manufacturing of nonwoven materials for medicine was launched in Tver region

GMP News

Hexa – Nonwoven Materials LLC, a borrower of Industry Development Fund (IDF), has launched a new production facility for manufacturing high-tech specialized composite nonwoven materials for making the surgical sets, and also began to produce disposable clothing and surgical sets.

Scientists from Kazan developed a drug for muscle weakness

GMP News

Biologists from Kazan have developed a new drug capable of suppressing myasthenia (muscle weakness) without inducing strong side effects. According to Konstantin Petrov, a chemist from the Institute of Organic and Physical Chemistry of the Russian Academy of Sciences in Kazan, in recent years, the scientists have developed dozens of drugs to help patients with muscular weakness to survive and not feel tired all the time. Most of these drugs inhibit AChE enzyme, which decomposes acetylcholine, a “signal of action” used by neurons to control the muscle cells.

Sechenov University establishes the Institute of Bionic Technology and Engineering

GMP News

The Institute of Bionic Technology and Engineering was established in March 2018 at Sechenov University’s Biomedicine Science and Technology Park. The key objectives of the Institute include the development of artificial organs and bionic prostheses, hemocompatible anticoagulant coatings for implants, as well as tissue engineering, intelligent diagnostics, and organs on chips.

Russia officially joined the MEDICRIME Convention

GMP News

The Russian Minister of Health Veronika Skvortsova deposited the instrument of ratification of the Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health (MEDICRIME Convention) with the Secretary General of the Council of Europe Thorbjørn Jagland.

Russian pharmacy market increased by 6.5% in ruble terms in 2017

GMP News

In 2017, 5065.8 million packages of drugs worth 940.7 billion rubles (in retail prices) were sold through the pharmacies in Russia. This is 6.5% higher than in 2016 in value terms and 3.5% higher in physical terms.

Russian pharma companies released the drugs worth 333.6 billion rubles in 2017

GMP News

For Russian pharmaceutical manufacturers, the overall results of 2017 were not impressive at all, to put it mildly. In total, last year, Russia manufactured about 4.5 billion packages of medicinal products, which is only 0.7% more than for 2016. The ruble-denominated figure for the same period looks better reaching 6.1%. However, it is still not even close to the pace demonstrated by the Russian pharmaceutical industry in 2015-2016.